Real-World Evidence on Lenvatinib plus Everolimus in Patients with Pre-Treated Advanced Renal Cell Carcinoma
In this MEDtalk, Philipp Ivanyi provides you with an overview of a study about subsequent therapy in kidney cancer presented at ASCO GU 2024. The study focused on the combination of lenvatinib and everolimus for advanced kidney cancer, particularly in patients who had received multiple prior treatment lines. The analysis highlighted the combination’s potential effectiveness, even in patients heavily pre-treated.
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.